Synthesis of β-Hydroxy-β-(fluoronitrophenyl)alanines:  Vital Components in the Assembly of Biologically Active Cyclic Peptides

1999 ◽  
Vol 1 (2) ◽  
pp. 295-298 ◽  
Author(s):  
Craig A. Hutton
Biopolymers ◽  
1981 ◽  
Vol 20 (9) ◽  
pp. 1785-1791 ◽  
Author(s):  
Nobuo Izumiya ◽  
Tetsuo Kato ◽  
Michinori Waki

Blood ◽  
2006 ◽  
Vol 107 (3) ◽  
pp. 1070-1077 ◽  
Author(s):  
Federico Perosa ◽  
Elvira Favoino ◽  
Maria Antonietta Caragnano ◽  
Franco Dammacco

Abstract Heterogeneity of the effector functions displayed by rituximab and other anti-CD20 monoclonal antibodies (mAbs) apparently recognizing the same CD20 epitope suggests that additional mechanisms, probably related to mAb fine specificity, are responsible for B-cell depletion. To improve our understanding of rituximab's function, its fine specificity was investigated by means of phage display peptide library (PDPL)-expressing 7-mer cyclic (c7c) or 7-/12-mer linear peptides. Rituximab-specific c7c PDPL-derived clone insert sequences expressed the motif A(S)NPS overlapping the human CD20 170ANPS173. P172 was the most critical for rituximab binding, since its replacement with S172 (of mouse CD20) abolished the reactivity. The WPXWLE motif expressed by the linear PDPL-derived clone insert sequences could only be aligned to the reverse-oriented 161WPXWLE156 of acid sphingomyelinase-like phosphodiesterase 3b precursor (ASMLPD), though linear peptides bearing WPXWLE competed with cyclic ones for rituximab-paratope binding. Anti-CD20 mAb 1F5 only displayed a reactivity profile similar to that of rituximab, which also reacted with ASMLPD-derived peptides. Peptides induced antibodies with specificity and effector functions similar to those of rituximab. Our results show a unique fine specificity of rituximab, define the molecular basis for the lack of rituximab reactivity with mouse CD20 (mCD20), and the potential of targeting CD20 in an active immunotherapy setting. A possible rituximab interaction with ASMLPD is suggested.


2016 ◽  
Vol 14 (2) ◽  
pp. 701-710 ◽  
Author(s):  
P. R. Werkhoven ◽  
M. Elwakiel ◽  
T. J. Meuleman ◽  
H. C. Quarles van Ufford ◽  
J. A. W. Kruijtzer ◽  
...  

An orthogonally alkyne functionalized TAC-scaffold was used for molecular construction of biologically active gp120 protein mimics containing different peptide loops.


Author(s):  
Kanda Bala Bhavana ◽  
A. Narendra Babu ◽  
J. Naga Lakshmi ◽  
B. Deepthi ◽  
G. Kavya

The current review aimed to provide a comprehensive overview of Bioactive compounds and pharmacological uses, of Linum usitatissimum, and to list its significant therapeutic benefits. From various studies, researchers specified the pharmacological properties of flaxseed. The phytoconstituents like lignan and ? linolenic acid are the richest of flaxseeds. It is also a chief source for soluble fiber, high-quality protein, and antioxidants. Its long trip from old era to the 21st century from being a medication in old age opened the way for a broad populace. Linolenic acid, linoleic acid, lignans, polysaccharides cyclic peptides, alkaloids, cadmium and cyanogenic glycosides were some of the biologically active chemicals and elements. Flaxseed extracts containing lignan or ? linolenic acid were often the focus of biological and clinical research. Some beneficial outcomes for health include decreasing cardiovascular illnesses, atherosclerosis, diabetes, cancer and arthritis, osteoporosis, and autoimmune illnesses, as well as neuroscience. Some Proteins present in flaxseed helps in prevention and cure for cardiovascular disease and reinforce the immune system. This present review focuses briefly on a pharmacological properties and laboratory outcomes of flaxseed diet.


2019 ◽  
Vol 23 (1) ◽  
pp. 38-75 ◽  
Author(s):  
Smritilekha Bera ◽  
Dhananjoy Mondal

Natural cyclic peptides are conformationally constrained notable biomolecules and reveal several drug-like properties such as high binding affinity, metabolic stability, target selectivity, bioavailability, low toxicity and flexibility. They have attracted a lot of attention as alternative sources of new drugs to traditional small molecules in drug discovery. Compared to classical medicines, cyclic peptides with a novel mechanism of action are attractive for their potential therapeutic applications particularly for cancer therapy and several diseases caused by resistant and non-resistant bacteria, virus, and fungi. Herein, we provide an overview of the naturally occurring biologically active cyclic peptide therapeutic landscape, including promising candidates, which are under trial in different stages for future and/or clinically used drugs against different diseases. This will certainly be an essential resource for upcoming and existing researchers and scientists within industry and academia in medicinal, bioorganic, and natural product chemistry.


Peptides ◽  
2011 ◽  
Vol 32 (12) ◽  
pp. 2504-2510 ◽  
Author(s):  
Alberto Bryan ◽  
Leroy Joseph ◽  
James A. Bennett ◽  
Herbert I. Jacobson ◽  
Thomas T. Andersen

2017 ◽  
Vol 38 (2) ◽  
pp. 85 ◽  
Author(s):  
Munish Puri

Algae are spread in diversified ecosystems that include marine, freshwater, desert and hot springs and even snow and ice environments. Algae are classified as multicellular large sea weeds (macroalgae) or unicellular microalgae. Macroalgae are targeted for mining of natural biologically active components, which include proteins, linear peptides, cyclic peptides, and amino acids1. Recently, microalgae have been exploited for the production of high-value compounds such as lipids (omega-3 fatty acids), enzymes, polymers, toxins, antioxidants, and pigments (carotenoids)2. Thus, algal biotechnology is defined as ‘the technology developed using algae (macro or micro) to make or modify bioactive compounds, or products (nutritional supplements, fine chemicals) and renewable fuels for specific use’.


Sign in / Sign up

Export Citation Format

Share Document